AlphAIAlphAI — Financial news for AI agents
tradingview.com$PRTA

Prothena 10% Owner Purchased Shares Worth Over $1.2M

William P. Scully, a 10% owner of Prothena, bought 150,000 shares in two transactions, totaling $1.22M. The average prices were $8.1852 and $8.0705 per share. Scully now directly owns 1.19M shares and indirectly owns 716,000 shares, according to an SEC filing.

Original reporting
tradingview.com
Published Oct 26, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Prothena 10% Owner Purchased Shares Worth Over $1.2M — source image
Source · tradingview.com
Decision brief

The 30-second read

$PRTABullishLow
01

Why it matters

The insider buy may provide short‑term price support but does not indicate a major strategic shift.

02

Market read

A modest insider purchase in a micro‑cap biotech; limited broader market impact.

03

What to watch

The filing does not disclose the buyer's rationale or any upcoming catalyst for the company.

Relevance 5/10Novelty 6/10Timing: after-hours

Background

Prothena Corp (NASDAQ:PRTA) filed a Form 4 showing a 10% owner purchased shares worth $1.22 M.

Company-level read

Ticker impact

$PRTABullishMedium confidence
Context

Form 4 filing shows a 10% owner bought 150,000 shares for $1.22 M, increasing his stake.

Expected impact

likely modest upward pressure as the market prices in the insider buy

Evidence & confidence

The buyer is a significant shareholder; the transaction size is material for a micro‑cap biotech and could attract short‑term buying.

Market effects

Sector

Limited; may slightly boost sentiment toward biotech insider activity.

Regional

None

Global

None

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a strong bullish signal.

Key entities

  • Insider
    William P. Scully

    10% owner of Prothena who made the purchase.

Read at source← All news

Related articles

$PRTAMedAI 8/10

Prothena Corporation plc: Prothena Reports Third Quarter 2026 Financial Results and Business Highlights

Prothena reported Q3 2026 net loss of $16.5M and 9M net loss of $2.4M, with $272.2M in cash. Coramitug showed reduced hsCRP in Phase 2 trial. Roche and Novo highlight prasinezumab and coramitug for Parkinson's and ATTR-CM. Phase 3 trials expected to complete in 2029. Prothena has $650M in upfront payments and potential $2.25B in milestones. Preclinical programs include TDP-43 CYTOPE and PRX012-TfR.

finanznachrichten.de
$PRTAMed

Prothena Reports Third Quarter 2026 Financial Results and Business Highlights

PROTHENA CORP PUBLIC LTD CO (PRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Prothena Reports Third Quarter 2026 Financial Results an d Business Highlights • Net cash used in operating and investing activities was $12.0 million in the third quarter and net cash used in operating and investing activities was $8.9 million for the

SEC EDGAR 8-K
$PRTAMed

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

Prothena (PRTA) reported Q2 2026 adjusted loss per share of 32 cents, narrower than the Zacks estimate of a 39-cent loss. Revenues were $1.01 million versus $4.4 million a year earlier, mainly collaboration revenue from Bristol Myers Squibb (BMY) for PRX019. Prothena had $330.3 million cash, no debt, and reaffirmed 2026 net cash use guidance of $18-$23 million.

tradingview.com
$PRTAMed

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

PROTHENA CORP PUBLIC LTD CO (PRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Prothena Reports Second Quarter 2026 Financial Results an d Business Highlights • Net cash used in operating and investing activities was $25.7 million in the second quarter, and net cash provided by operating and investing activities was $3.2 million f

SEC EDGAR 8-K
$PLTRMed

Palantir’s Tech Chief Wants to Sell $50 Million in Stock After the AI Crash

Palantir's CTO, Shyam Sankar, filed to sell 300,000 shares worth $50.76M. The filing follows a 9.73% stock drop on Nov 5, though shares have since partially recovered. Sankar's sales are part of a pre-planned 10b5-1 schedule. Palantir reported Q3 revenue of $2.313B, up 96%, and raised full-year guidance. The stock trades at high multiples, with executives often selling on a schedule.

247wallst.com